Research
Hormonal
The monthly growth rates were 83.9% for Ozempic and 119.2% for Wegovy.
High monthly growth rates indicate a significant trend towards the use of GLP-1 receptor agonists for weight loss.
StrongSupportsmedium confidence
The monthly growth rates were 83.9% for Ozempic, 119.2% for Wegovy.
Why this rating
Based on the retrospective cohort study design involving a large database.
Source
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022
Jonathan H. Watanabe et al. · Journal of the American Pharmacists Association · 2023
cohortCited 179×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →